# Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

> **NCT03213587** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03213587
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-01
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213587, "Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03213587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*